Bruker Corporation $BRKR Shares Sold by Legacy Capital Group California Inc.

Legacy Capital Group California Inc. lowered its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 41.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,948 shares of the medical research company’s stock after selling 9,247 shares during the period. Legacy Capital Group California Inc.’s holdings in Bruker were worth $468,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Allworth Financial LP lifted its position in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the period. Federated Hermes Inc. grew its holdings in shares of Bruker by 6.7% in the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock worth $284,000 after acquiring an additional 380 shares during the period. Parallel Advisors LLC increased its stake in Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares in the last quarter. State of Michigan Retirement System increased its stake in Bruker by 1.9% in the 1st quarter. State of Michigan Retirement System now owns 26,693 shares of the medical research company’s stock valued at $964,000 after purchasing an additional 500 shares in the last quarter. Finally, CWM LLC raised its holdings in Bruker by 49.8% during the fourth quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock worth $77,000 after purchasing an additional 542 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Stock Performance

Bruker stock opened at $59.83 on Wednesday. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $64.54. The company has a market capitalization of $9.11 billion, a price-to-earnings ratio of -249.29, a PEG ratio of 1.89 and a beta of 1.29. The stock has a fifty day moving average of $53.80 and a two-hundred day moving average of $45.65. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $823.40 million for the quarter, compared to the consensus estimate of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The business’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts anticipate that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, June 22nd. Bruker’s dividend payout ratio (DPR) is currently -83.33%.

Analyst Ratings Changes

BRKR has been the topic of several research reports. Citigroup upped their target price on Bruker from $44.00 to $60.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Barclays lifted their price target on Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Stifel Nicolaus set a $45.00 price objective on shares of Bruker in a research report on Friday, May 8th. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. raised their target price on shares of Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $56.79.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.